558 related articles for article (PubMed ID: 18836691)
21. Penetration of second-, third-, and fourth-generation topical fluoroquinolone into aqueous and vitreous humour in a rabbit endophthalmitis model.
Yağci R; Oflu Y; Dinçel A; Kaya E; Yağci S; Bayar B; Duman S; Bozkurt A
Eye (Lond); 2007 Jul; 21(7):990-4. PubMed ID: 16732216
[TBL] [Abstract][Full Text] [Related]
22. In vitro activity of moxifloxacin against common clinical bacterial isolates in Taiwan.
Sheng WH; Wang JT; Chen YC; Chang SC; Luh KT
J Microbiol Immunol Infect; 2001 Sep; 34(3):178-84. PubMed ID: 11605808
[TBL] [Abstract][Full Text] [Related]
23. Comparison of in vitro susceptibilities of Gram-positive cocci isolated from ocular infections against the second and fourth generation quinolones at a tertiary eye care centre in South India.
Reddy AK; Garg P; Alam MR; Gopinathan U; Sharma S; Krishnaiah S
Eye (Lond); 2010 Jan; 24(1):170-4. PubMed ID: 19229279
[TBL] [Abstract][Full Text] [Related]
24. Comparison of besifloxacin, gatifloxacin, and moxifloxacin against strains of pseudomonas aeruginosa with different quinolone susceptibility patterns in a rabbit model of keratitis.
Sanders ME; Moore QC; Norcross EW; Sanfilippo CM; Hesje CK; Shafiee A; Marquart ME
Cornea; 2011 Jan; 30(1):83-90. PubMed ID: 20847656
[TBL] [Abstract][Full Text] [Related]
25. The safety profile of moxifloxacin and other fluoroquinolones in special patient populations.
Iannini PB
Curr Med Res Opin; 2007 Jun; 23(6):1403-13. PubMed ID: 17559736
[TBL] [Abstract][Full Text] [Related]
26. [New fluoroquinolones: levofloxacin, moxifloxacin and gatifloxacin].
Hoepelman I
Ned Tijdschr Geneeskd; 2004 Oct; 148(43):2115-21. PubMed ID: 15553354
[TBL] [Abstract][Full Text] [Related]
27. Effectiveness of fluoroquinolones against Mycobacterium abscessus in vivo.
Caballero AR; Marquart ME; O'Callaghan RJ; Thibodeaux BA; Johnston KH; Dajcs JJ
Curr Eye Res; 2006 Jan; 31(1):23-9. PubMed ID: 16421016
[TBL] [Abstract][Full Text] [Related]
28. Third- and fourth-generation fluoroquinolones: retrospective comparison of endophthalmitis after cataract surgery performed over 10 years.
Jensen MK; Fiscella RG; Moshirfar M; Mooney B
J Cataract Refract Surg; 2008 Sep; 34(9):1460-7. PubMed ID: 18721704
[TBL] [Abstract][Full Text] [Related]
29. Benzalkonium chloride enhances antibacterial activity of gatifloxacin and reduces its propensity to select for fluoroquinolone-resistant strains.
Hesje CK; Borsos SD; Blondeau JM
J Ocul Pharmacol Ther; 2009 Aug; 25(4):329-34. PubMed ID: 19650708
[TBL] [Abstract][Full Text] [Related]
30. Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis.
Johnson JL; Hadad DJ; Boom WH; Daley CL; Peloquin CA; Eisenach KD; Jankus DD; Debanne SM; Charlebois ED; Maciel E; Palaci M; Dietze R
Int J Tuberc Lung Dis; 2006 Jun; 10(6):605-12. PubMed ID: 16776446
[TBL] [Abstract][Full Text] [Related]
31. In vitro susceptibility of bacterial keratitis isolates to fourth-generation fluoroquinolones.
Chawla B; Agarwal P; Tandon R; Titiyal JS; Sharma N; Agarwal T; Navak N; Satpathy G
Eur J Ophthalmol; 2010; 20(2):300-5. PubMed ID: 19924668
[TBL] [Abstract][Full Text] [Related]
32. Topical antibacterial therapy for mycobacterial keratitis: potential for surgical prophylaxis and treatment.
Abshire R; Cockrum P; Crider J; Schlech B
Clin Ther; 2004 Feb; 26(2):191-6. PubMed ID: 15038942
[TBL] [Abstract][Full Text] [Related]
33. Comparison of corneal and aqueous humor penetration of moxifloxacin, gatifloxacin and levofloxacin during keratoplasty.
Fukuda M; Yamada M; Kinoshita S; Inatomi T; Ohashi Y; Uno T; Shimazaki J; Satake Y; Maeda N; Hori Y; Nishida K; Kubota A; Nakazawa T; Shimomura Y
Adv Ther; 2012 Apr; 29(4):339-49. PubMed ID: 22529026
[TBL] [Abstract][Full Text] [Related]
34. Endophthalmitis after uncomplicated cataract surgery with the use of fourth-generation fluoroquinolones: a retrospective observational case series.
Moshirfar M; Feiz V; Vitale AT; Wegelin JA; Basavanthappa S; Wolsey DH
Ophthalmology; 2007 Apr; 114(4):686-91. PubMed ID: 17184840
[TBL] [Abstract][Full Text] [Related]
35. [Analysis on susceptibility of ocular bacterial pathogens to four kinds of fluoroquinolone].
Wang ZQ; Li L; Li R; Luo SY; Bai XQ; Liang QF; Deng SJ; Sun XG
Zhonghua Yan Ke Za Zhi; 2008 Mar; 44(3):233-6. PubMed ID: 18785547
[TBL] [Abstract][Full Text] [Related]
36. Randomized clinical study for comparative evaluation of fourth-generation fluoroquinolones with the combination of fortified antibiotics in the treatment of bacterial corneal ulcers.
Shah VM; Tandon R; Satpathy G; Nayak N; Chawla B; Agarwal T; Sharma N; Titiyal JS; Vajpayee RB
Cornea; 2010 Jul; 29(7):751-7. PubMed ID: 20489580
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetics of moxifloxacin and high-dose levofloxacin in severe lower respiratory tract infections.
Kontou P; Manika K; Chatzika K; Papaioannou M; Sionidou M; Pitsiou G; Kioumis I
Int J Antimicrob Agents; 2013 Sep; 42(3):262-7. PubMed ID: 23830621
[TBL] [Abstract][Full Text] [Related]
38. Comparative in vitro activity of three fluoroquinolones against clinical isolates by E test.
Madhusudhan KT; Counts C; Lody C; Carter O; Dodson S; Ojha N
Chemotherapy; 2003 Jul; 49(4):184-8. PubMed ID: 12886053
[TBL] [Abstract][Full Text] [Related]
39. Fourth-generation fluoroquinolones: new topical agents in the war on ocular bacterial infections.
Mah FS
Curr Opin Ophthalmol; 2004 Aug; 15(4):316-20. PubMed ID: 15232471
[TBL] [Abstract][Full Text] [Related]
40. Susceptibility comparisons of normal preoperative conjunctival bacteria to fluoroquinolones.
Hori Y; Nakazawa T; Maeda N; Sakamoto M; Yokokura S; Kubota A; Inoue T; Nishida K; Tano Y
J Cataract Refract Surg; 2009 Mar; 35(3):475-9. PubMed ID: 19251140
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
